Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

A new tool for detection of type I interferon activation in systemic lupus erythematosus

Kyriakos A Kirou* and George D Kalliolias

Author Affiliations

Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA

For all author emails, please log on.

Arthritis Research & Therapy 2010, 12:138  doi:10.1186/ar3114


See related research by Li et al., http://arthritis-research.com/content/12/3/R90

Published: 26 August 2010

Abstract

The IFN-I pathway is activated in systemic lupus erythematosus (SLE) and appears to be important in the pathogenesis of the disease. As a result, several clinical trials of anti-IFN monoclonal antibodies, which hold promise to control the disease, have been launched. Additionally, activation of IFN-I might be important in the prognosis and activity assessment of the disease. Therefore, new biomarkers that reflect activity of the IFN-I pathway and are simple to measure, such as the monocyte CD64 receptor, are expected to have a great impact on the management of SLE, if properly validated.